Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;13(1):165-182.
doi: 10.1007/s40120-023-00569-3. Epub 2024 Jan 4.

Impact of Migraine on Daily Life: Results of the Observational survey of the Epidemiology, Treatment, and Care of Migraine (OVERCOME [Japan]) Study

Etsuko Awaki  1 , Takao Takeshima  2 , Yasuhiko Matsumori  3 , Koichi Hirata  4 , Naoki Miyazaki  5 , Ryo Takemura  5 , Satoshi Osaga  6 , Yoshinori Tanizawa  7 , Mika Komori  6
Affiliations

Impact of Migraine on Daily Life: Results of the Observational survey of the Epidemiology, Treatment, and Care of Migraine (OVERCOME [Japan]) Study

Etsuko Awaki et al. Neurol Ther. 2024 Feb.

Abstract

Introduction: The impacts of migraine on daily life, including daily activities and fundamental health indicators (sleep and mental health), have not been described in detail for people with migraine in Japan.

Methods: The cross-sectional ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study was conducted between July and September 2020. Impacts of migraine on housework, family/social/leisure activities, driving, and sleep were assessed using questions from the Migraine Disability Assessment (MIDAS), Migraine-Specific Quality-of-Life Questionnaire, and Impact of Migraine on Partners and Adolescent Children scales and questions developed for OVERCOME (Japan). The Migraine Interictal Burden Scale (MIBS-4) evaluated burden on days without headaches. Depression and anxiety were assessed with the Patient Health Questionnaire (PHQ-8) and Generalized Anxiety Disorder (GAD-7) scales, respectively. Impacts on daily life were also described across MIDAS/MIBS-4 categories.

Results: Among 17,071 respondents with migraine, 24.8% required assistance with housework at least sometimes. Migraine interfered with relationships, leisure, and social activities at least sometimes for 31.8%, 41.6%, and 18.0% of respondents, respectively. Between headache days, 26.8% of respondents worried about planning social/leisure activities at least sometimes. Among respondents living with family (N = 13,548), migraine also had impacts on participation in and enjoyment of family activities. Among respondents who drove (N = 10,921), 43.9% reported that symptoms interfered with driving at least sometimes. Migraine interfered with sleep and mood at least sometimes for 52.7% and 70.7% of respondents, respectively. PHQ-8 and GAD-7 thresholds for clinical depression and anxiety were met by 28.6% and 22.0% of respondents, respectively. Impact of migraine on daily life increased with increasing severity of MIDAS/MIBS-4 categories.

Conclusion: The burden of migraine on daily activities, sleep, and mental health is substantial for people with migraine in Japan. In clinical practice, it is important to evaluate the impact of migraine on daily life in addition to migraine symptoms.

Keywords: Automobile driving; Daily life; Family; Household work; Japan; Leisure activities; Mental health; Migraine disorders; Sleep; Social participation.

PubMed Disclaimer

Conflict of interest statement

Etsuko Awaki reports lecture fees/honoraria from Amgen, Daiichi Sankyo Company, Limited, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Takao Takeshima received research funding/collaborative research expenses from Biohaven, Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Lundbeck Japan K.K., and Shionogi & Co., Ltd., and reports personal fees from Amgen Astellas BioPharma K.K., Daiichi Sankyo Company, Limited, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Takao Takeshima also acted as an advisor to Hedgehog MedTech, Inc. and Sawai Pharmaceutical Co., Ltd. Yasuhiko Matsumori reports personal consultancy fees from Amgen Astellas BioPharma K.K., Daiichi Sankyo Company, Limited, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. during the conduct of the study. Koichi Hirata received research funding from the Japanese Ministry of Health, Labour and Welfare and the Japan Agency for Medical Research and Development, and reports personal fees from AbbVie GK, Amgen Astellas BioPharma K.K., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly Japan K.K., MSD Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., and Sawai Pharmaceutical Co., Ltd. Naoki Miyazaki and Ryo Takemura are employees of Keio University. Keio University received funding from Eli Lilly Japan K.K. for the statistical analyses reported in this manuscript. Satoshi Osaga, Yoshinori Tanizawa, and Mika Komori are employees of Eli Lilly Japan K.K. and own minor shares in Eli Lilly and Company.

Figures

Fig. 1
Fig. 1
Impact of migraine on housework. Direct impacts (impact on the respondents’ ability to do housework): a MIDAS responses (N = 17,071); b IMPAC Part A response for respondents living with any family members (N = 13,548; respondents who selected “not applicable” are not shown: n = 1800 [13.3%]). Indirect impacts (impact on other household members): c MSQ response for respondents living with any family members (N = 13,548); d IMPAC Part B response for respondents living with a partner/spouse (N = 9807; respondents who selected “not applicable” are not shown: n = 1842 [18.8%]). All combined percentages were calculated from source data, rounded to one decimal place. IMPAC Impact of Migraine on Partners and Adolescent Children; MIDAS Migraine Disability Assessment; MSQ Migraine-Specific Quality-of-Life Questionnaire; SD standard deviation
Fig. 2
Fig. 2
Impact of migraine on family, social, and leisure activities. a MIDAS response (N = 17,071); b impact on exercise (N = 17,071; respondents who selected “not applicable” are not shown, n = 1609 [9.4%]); c MSQ responses (N = 17,071); d IMPAC responses for respondents living with any family members (Part A, N = 13,548; respondents who selected “not applicable” are not showna), living with a partner/spouse (Part B, N = 9807; respondents who selected “not applicable” are not shown: n = 1844 [18.8%]), and living with children aged 13–18 years (Part C, N = 2358; respondents who selected “not applicable” are not shown: n = 464 [19.7%]). All combined percentages were calculated from source data, rounded to one decimal place. an = 2232 (16.5%) for “not participate in family activity at home,” n = 3262 (24.1%) for “not do anything physical with family,” and n = 2812 (20.8%) for “involvement in/enjoyment of family activities significantly reduced.” IMPAC Impact of Migraine on Partners and Adolescent Children; MIDAS Migraine Disability Assessment; MSQ Migraine-Specific Quality-of-Life Questionnaire; SD standard deviation
Fig. 3
Fig. 3
Impact of migraine on driving. a Impact of pain and symptoms on respondents’ ability to drive a car (N = 10,921; respondents who selected “not applicable” are not shown, n = 419 [3.8%]); b frequency of driving while having a migraine attack in the past 12 months, stratified by pain level of migraine attack (N = 10,921); c frequency of not driving due to migraine or severe headache in the past 12 months (N = 10,921); d reasons for not driving due to migraine or headache in the past 12 monthsa (respondents who answered “yes” in part c, N = 3566). All combined percentages were calculated from source data, rounded to one decimal place. aRespondents could provide more than one reason for not driving
Fig. 4
Fig. 4
Impact of migraine on sleep. a Impact of pain and symptoms on respondents’ ability to sleep (N = 17,071; respondents who selected “not applicable” are not shown, n = 524 [3.1%]); b how often respondents needed to take medication at night (from midnight to 5:59 AM) (N = 17,071). All combined percentages were calculated from source data, rounded to one decimal place
Fig. 5
Fig. 5
Impact of migraine on mental health. a Impact of pain and symptoms on respondents’ mood (N = 17,071; respondents who selected “not applicable” are not shown, n = 360 [2.1%]); b depression, measured using the PHQ-8 (N = 17,071); c anxiety, measured using the GAD-7 (N = 17,071). All combined percentages were calculated from source data, rounded to one decimal place. GAD-7 seven-item Generalized Anxiety Disorder questionnaire; PHQ-8 eight-item Patient Health Questionnaire
Fig. 6
Fig. 6
Interictal burden of migraine, assessed using the MIBS-4. Responses to each of the MIBS-4 items are shown. Percentages shown are proportions of the full migraine group (N = 17,071). Not shown are the percentages of respondents who selected “not applicable”; this was n = 2643 (15.5%), n = 2105 (12.3%), n = 1968 (11.5%), and n = 1961 (11.5%) for each of the four items, respectively. All combined percentages were calculated from source data, rounded to one decimal place. MIBS Migraine Interictal Burden Scale
See this image and copyright information in PMC

References

    1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. doi: 10.1177/0333102417738202. - DOI - PubMed
    1. Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, on behalf of Lifting The Burden: the Global Campaign against Headache Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137. doi: 10.1186/s10194-020-01208-0. - DOI - PMC - PubMed
    1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646–657. doi: 10.1046/j.1526-4610.2001.041007646.x. - DOI - PubMed
    1. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–349. doi: 10.1212/01.wnl.0000252808.97649.21. - DOI - PubMed
    1. Matsumori Y, Ueda K, Komori M, et al. Burden of migraine in Japan: results of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. Neurol Ther. 2022;11(1):205–222. doi: 10.1007/s40120-021-00305-9. - DOI - PMC - PubMed

LinkOut - more resources